In laboratories at Stanford Medicine, researchers have fashioned a molecular tool small enough to slip through the narrow gates that biology and engineering impose on gene therapy — a constraint that has quietly limited medicine's ability to rewrite the instructions of disease. Their creation, TIGRa, activates rather than edits genes, and its compactness allows it to travel inside viral messengers that the body will actually accept. Tested first in the eye, where sight offers an honest and immediate verdict, it preserved a measure of vision in mice that would otherwise have gone blind — a mode